ADME toxicology Testing Global Market Report 2024

The ADME toxicology testing market size has grown rapidly in recent years. It will grow from $9.3 billion in 2023 to $10.34 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth observed in the historical period can be attributed to several factors, including stringent regulatory requirements, increased drug development activities, growing concerns about drug safety, advancements in in vitro testing methods, and a rise in the outsourcing of toxicology studies. These elements collectively contributed to the expansion and evolution of the ADME toxicology testing industry during that period.

The ADME toxicology testing market size is expected to see rapid growth in the next few years. It will grow to $15.77 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the forecast period can be attributed to several factors, including the rapid expansion of biopharmaceuticals, an increasing emphasis on personalized medicine, the emergence of advanced therapies, enhanced predictive toxicology models, and a global increase in chemical safety testing. Key trends expected in the forecast period encompass the expansion of biomarker applications, the integration of multi-omics data, regulatory emphasis on in vitro testing, collaborations and partnerships within the industry, and continuous advancements in technology. These trends collectively contribute to the ongoing evolution and advancement of ADME toxicology testing methodologies.

The burgeoning demand for newly developed pharmaceutical substances, known as novel drugs, is expected to be a significant catalyst propelling the expansion of the ADME toxicology testing market. Novel drugs constitute pharmaceutical substances that haven't been previously approved or marketed for therapeutic use. ADME toxicity testing plays a pivotal role in the drug development process, ensuring the safety of these novel drugs by verifying their lack of harmful toxins within the body. As highlighted by the US Food and Drug Administration's data, there was an approval of 53 novel drugs in 2022, a notable increase from the 50 drugs approved in the preceding year. This upward trend in novel drug approvals underscores the escalating demand for such pharmaceutical entities, consequently driving the growth of the ADME toxicology testing market.

The thriving pharmaceutical industry is poised to act as a substantial driver propelling the expansion of the ADME toxicology testing market. This sector involves the exploration, development, and manufacturing of drugs and medications by governmental and private entities. In drug development, the pharmaceutical industry heavily relies on ADME toxicology testing to assess the absorption, distribution, metabolism, and excretion (ADME) properties of drug candidates and evaluate their potential toxicity. This testing holds paramount importance in predicting a drug's behavior within the human body, encompassing factors such as absorption rates, distribution to target tissues, metabolism, and elimination. As indicated in reports from IQVIA Inc. in May 2021, the projected total expenditure on pharmaceuticals in the US is estimated to range between $380 and $400 billion by 2025, showcasing an anticipated growth from $359 billion in 2020 at a compound annual growth rate of 0-3%. This considerable expansion in pharmaceutical spending reflects the robust growth trajectory of the pharmaceutical industry, consequently fueling the advancement of the ADME toxicology testing market.

Technological advancements are emerging as a pivotal trend gaining traction within the ADME toxicology testing market. Major companies within this sector are actively introducing innovative assay solutions embedded with advanced technologies, aiming to fortify their market standing. An illustrative example occurred in April 2022 when Charles River Laboratories International Inc., a US-based pharmaceutical company, partnered with Valo Health Inc., a US-based AI-health solutions provider, to unveil Logica. This cutting-edge AI-based drug development solution harnesses Valo’s Opal Computational Platform, utilizing AI to offer ADME toxicology testing services and other drug delivery solutions, thereby revolutionizing drug development methodologies.

Prominent entities operating within the ADME toxicology testing market are integrating advanced technologies such as Cyprotex e-Store, fostering a seamless avenue for online ordering of ADME-Tox services. ADME-Tox services serve the purpose of reducing development costs and time, mitigating the risk of failure in later stages, and facilitating the identification of optimal candidates for clinical development. For instance, in October 2023, Evotec SE, a Germany-based biotechnology company, launched the Cyprotex e-Store, an e-commerce platform designed to provide convenient online access to the company's comprehensive range of ADME-Tox services. This platform streamlines and expedites the purchasing process, enabling registered users to assess and order Cyprotex' offerings at any time, seven days a week. The e-Store grants instant access to pricing details and comprehensive protocols online, allowing users to easily place, track, and reorder services as needed. This efficient platform significantly reduces service lead times, ensuring users receive their data promptly, thus enhancing overall efficiency in ADME-Tox testing processes.

In September 2022, BioIVT, a U.S.-based provider of drug development solutions, successfully acquired XenoTech for an undisclosed amount. This strategic acquisition marks a significant milestone for BioIVT, as it not only complements and strengthens its existing product portfolio but also facilitates the expansion of its offerings into new geographical regions and a wider customer base. XenoTech, a U.S.-based contract research organization, specializes in providing ADME-toxicology testing services. The acquisition underscores BioIVT's commitment to enhancing its capabilities and presence in the field of drug development.

Major companies operating in the adme toxicology testing market report are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Laboratory Corporation of America Holdings, Corning Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Lonza Group AG, Dassault Systèmes SE, Catalent Inc., Charles River Laboratories International Inc., Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Curia Global Inc, Promega Corporation, Takara Bio Inc, AB Sciex LLC, QPS Holdings LLC, Simulations Plus Inc., Cyprotex, XenoTech LLC, BioIVT LLC, Absorption Systems, Creative Bioarray, SOLVO Biotechnology Rt., Creative Biolabs Inc, Gentronix Limited, Admecell Inc., Molecular Discovery Ltd.


North America was the largest region in the ADME toxicology testing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adme toxicology testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the adme toxicology testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products associated with ADME toxicology testing include instruments, software solutions, assay systems, reagents, and other related items. Instruments are specialized devices or tools designed for specific purposes, commonly utilized in scientific, medical, or technical contexts. In the context of ADME toxicity testing, instruments are used for the measurement and analysis of readings. Various methods are employed in ADME toxicology testing, including cellular assay, biochemical assay, in silico, and ex-vivo approaches. These methods are complemented by technologies such as single-cell culture, high throughput screening, molecular imaging, omics technology, and other relevant technologies. ADME toxicology testing is applied to assess systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and other factors. Industries that benefit from these tests include cosmetics and household products, pharmaceuticals, the animal industry, the food industry, and others.

The ADME toxicology testing market research report is one of a series of new reports that provides ADME toxicology testing market statistics, including ADME toxicology testing industry global market size, regional shares, competitors with an ADME toxicology testing market share, detailed ADME toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the ADME toxicology testing industry. This ADME toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ADME toxicology testing market consists of revenues earned by entities by providing services such as drug discovery research, measuring gene expression, and preclinical efficacy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The ADME toxicology testing market also includes sales of ADMET predictors, and UV spectrophotometers, which are used in providing ADME toxicology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.